Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 3.25
(0.31%)
CNY 3.25
(0.31%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 262.1 Million CNY | 274.82% |
| 2022 | 69.93 Million CNY | -20.26% |
| 2021 | 87.69 Million CNY | 948.59% |
| 2020 | 8.36 Million CNY | -99.37% |
| 2019 | 1.32 Billion CNY | -36.09% |
| 2018 | 2.07 Billion CNY | 24.49% |
| 2017 | 1.66 Billion CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 274.14 Million CNY | 3.15% |
| 2024 Q2 | 326.85 Million CNY | 21.28% |
| 2024 Q3 | 502.25 Million CNY | 53.66% |
| 2023 Q3 | 177.36 Million CNY | 49.24% |
| 2023 FY | 262.1 Million CNY | 274.82% |
| 2023 Q4 | 262.1 Million CNY | 47.78% |
| 2023 Q2 | 118.84 Million CNY | 325.56% |
| 2023 Q1 | 27.92 Million CNY | -60.06% |
| 2022 Q1 | 111.03 Million CNY | 26.62% |
| 2022 FY | 69.93 Million CNY | -20.26% |
| 2022 Q4 | 69.93 Million CNY | -31.97% |
| 2022 Q3 | 102.78 Million CNY | -4.05% |
| 2022 Q2 | 107.12 Million CNY | -3.52% |
| 2021 FY | 87.69 Million CNY | 948.59% |
| 2021 Q4 | 87.69 Million CNY | -14.73% |
| 2021 Q2 | 60.11 Million CNY | 634.29% |
| 2021 Q3 | 102.84 Million CNY | 71.08% |
| 2021 Q1 | 8.18 Million CNY | -2.11% |
| 2020 Q3 | 32.7 Million CNY | -34.04% |
| 2020 FY | 8.36 Million CNY | -99.37% |
| 2020 Q1 | 1.35 Billion CNY | 2.26% |
| 2020 Q2 | 49.57 Million CNY | -96.35% |
| 2020 Q4 | 8.36 Million CNY | -74.43% |
| 2019 Q2 | 1.91 Billion CNY | 1.09% |
| 2019 Q4 | 1.32 Billion CNY | -30.76% |
| 2019 Q3 | 1.91 Billion CNY | -0.19% |
| 2019 FY | 1.32 Billion CNY | -36.09% |
| 2019 Q1 | 1.89 Billion CNY | -8.52% |
| 2018 Q4 | 2.07 Billion CNY | -17.24% |
| 2018 Q3 | 2.5 Billion CNY | -4.31% |
| 2018 Q2 | 2.62 Billion CNY | 57.52% |
| 2018 Q1 | 1.66 Billion CNY | -0.21% |
| 2018 FY | 2.07 Billion CNY | 24.49% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 Q3 | 176.7 Million CNY | 118.42% |
| 2017 Q4 | 1.66 Billion CNY | 843.52% |
| 2017 FY | 1.66 Billion CNY | 0.0% |
| 2017 Q2 | 80.9 Million CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q3 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2015 Q3 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q2 | - CNY | -100.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q1 | 2.78 Million CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 1.45 Billion CNY | 81.946% |
| Shenzhen Glory Medical Co.,Ltd. | 269.54 Million CNY | 2.758% |